↓ Skip to main content

Vitex agnus castus

Overview of attention for article published in Drug Safety, November 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs
1 blog
twitter
1 X user
wikipedia
6 Wikipedia pages
video
2 YouTube creators

Citations

dimensions_citation
115 Dimensions

Readers on

mendeley
170 Mendeley
Title
Vitex agnus castus
Published in
Drug Safety, November 2012
DOI 10.2165/00002018-200528040-00004
Pubmed ID
Authors

Claudia Daniele, Joanna Thompson Coon, Max H. Pittler, Edzard Ernst

Abstract

Vitex agnus castus L. (VAC) [Verbenaceae] is a deciduous shrub that is native to Mediterranean Europe and Central Asia. Traditionally, VAC fruit extract has been used in the treatment of many female conditions, including menstrual disorders (amenorrhoea, dysmenorrhoea), premenstrual syndrome (PMS), corpus luteum insufficiency, hyperprolactinaemia, infertility, acne, menopause and disrupted lactation. The German Commission E has approved the use of VAC for irregularities of the menstrual cycle, premenstrual disturbances and mastodynia. Clinical reviews are available for the efficacy of VAC in PMS, cycle disorders, hyperprolactinaemia and mastalgia, but so far no systematic review has been published on adverse events or drug interactions associated with VAC. Therefore, this review was conducted to evaluate all the available human safety data of VAC monopreparations. Literature searches were conducted in six electronic databases, in references lists of all identified papers and in departmental files. Data from spontaneous reporting schemes of the WHO and national drug safety bodies were also included. Twelve manufacturers of VAC-containing preparations and five herbalist organisations were contacted for additional information. No language restrictions were imposed. Combination preparations including VAC or homeopathic preparations of VAC were excluded. Data extraction of key data from all articles reporting adverse events or interactions was performed independently by at least two reviewers, regardless of study design. Data from clinical trials, postmarketing surveillance studies, surveys, spontaneous reporting schemes, manufacturers and herbalist organisations indicate that the adverse events following VAC treatment are mild and reversible. The most frequent adverse events are nausea, headache, gastrointestinal disturbances, menstrual disorders, acne, pruritus and erythematous rash. No drug interactions were reported. Use of VAC should be avoided during pregnancy or lactation. Theoretically, VAC might also interfere with dopaminergic antagonists. Although further rigorous studies are needed to assess the safety of VAC, the data available seem to indicate that VAC is a safe herbal medicine.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 170 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Finland 1 <1%
Russia 1 <1%
Unknown 168 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 46 27%
Researcher 18 11%
Student > Master 18 11%
Other 11 6%
Student > Ph. D. Student 11 6%
Other 35 21%
Unknown 31 18%
Readers by discipline Count As %
Medicine and Dentistry 59 35%
Agricultural and Biological Sciences 18 11%
Nursing and Health Professions 12 7%
Pharmacology, Toxicology and Pharmaceutical Science 12 7%
Biochemistry, Genetics and Molecular Biology 10 6%
Other 22 13%
Unknown 37 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2023.
All research outputs
#2,367,639
of 25,374,917 outputs
Outputs from Drug Safety
#247
of 1,852 outputs
Outputs of similar age
#21,264
of 285,246 outputs
Outputs of similar age from Drug Safety
#83
of 812 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,852 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,246 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 812 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.